STK11 and KEAP1 mutations are also not reliable predictors of response to ICI therapy, given their association with a non-inflamed tumor microenvironment (TME) and frequent co-occurrence with mutations such as KRAS (31–33). This evidence concerns the gene KEAP1 and neoplasm.